Kumar S. Esophageal squamous cell carcinoma susceptibility of activin A receptor type 1C variants in Chinese population. World J Gastrointest Oncol 2025; 17(6): 102687 [DOI: 10.4251/wjgo.v17.i6.102687]
Corresponding Author of This Article
Shashank Kumar, PhD, Assistant Professor, Department of Biochemistry, Central University of Punjab, VPO Ghudda, Bathinda 151401, Punjab, India. shashankbiochemau@gmail.com
Research Domain of This Article
Biochemistry & Molecular Biology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Jun 15, 2025; 17(6): 102687 Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.102687
Esophageal squamous cell carcinoma susceptibility of activin A receptor type 1C variants in Chinese population
Shashank Kumar
Shashank Kumar, Department of Biochemistry, Central University of Punjab, Bathinda 151401, Punjab, India
Author contributions: Kumar S wrote the original draft, conceptualization, writing, reviewing and editing; read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: Author declares no conflicts of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shashank Kumar, PhD, Assistant Professor, Department of Biochemistry, Central University of Punjab, VPO Ghudda, Bathinda 151401, Punjab, India. shashankbiochemau@gmail.com
Received: October 28, 2024 Revised: January 28, 2025 Accepted: February 11, 2025 Published online: June 15, 2025 Processing time: 230 Days and 14.7 Hours
Abstract
Lin et al’s investigation on the association of activin A receptor type 1C (ACVR1C) (transforming growth factor beta type I receptor) single nucleotide polymorphisms (SNPs) with esophageal squamous cell carcinoma (ESCC) risk in the Chinese population is a scientific approach. This study explores the susceptibility of ACVR1C polymorphism towards ESCC in the Chinese population, highlighting the polymorphism’s potentiality as an early diagnostic and therapeutic target. The author assessed about a thousand ESCC Chinese patients’ samples for ACVR1C SNPs in a hospital-based cohort study using the ligation detection reaction method. Further, the hypothesis was tested using appropriate statistical genetic models and stratified analysis. ACVR1C SNPs can help assess ESCC susceptibility stratification and provide valuable information for individual diagnosis and treatment of ESCC patients. In order to account for confounding variables, find genuine SNP-disease relationships, boost statistical power, and make biological interpretation easier, it is imperative that genetic association studies of ESCC incorporate pertinent clinical aspects.
Core Tip: The present hospital-based case-control study investigates the activin A receptor type 1C (ACVR1C) single nucleotide polymorphisms association with the esophageal squamous cell carcinoma (ESCC) risk in a very small population. The author tried to stratify the association with the demographic profile of the patients but lacked association with the clinical characteristics of the test patients. ACVR1C expression should be studied in the samples as it is associated with cancer hallmarks and clinical outcomes in a cancer context-dependent manner. Next, the author should include the patients getting ESCC therapy as one of the groups as ACVR1C expression plays a role in chemotherapeutic response to cancer. These measures will provide useful information for clinical practice.
